KONFIDENT phase 3 trial results demonstrated significantly faster symptom relief with sebetralstat compared to placebo.

Immunosuppressive therapy may help reduce gastrointestinal (GI) symptoms among patients with systemic sclerosis (SSc), according to study results published in RMD Open.

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

National trends in keloid treatment revealed the greatest utilization of treatment among women and those in the finance and service industries.

The overall second primary malignancy point estimate was 5.8% for patients receiving chimeric antigen receptor T-cell therapy.

Results of a cross-sectional, observational study of UK biobank data suggest severe vitamin D deficiency may be associated with chronic widespread pain.

The decision to use b/tsDMARD monotherapy vs combination therapy with MTX when treating PsA is primarily based on patient satisfaction and drug tolerability.

No new safety concerns and consistent safety profiles were observed for long-term risankizumab use in patients with psoriasis and PsA.

Implementation of opt-out emergency department syphilis screening leads to a dramatic increase in screening and diagnosis, especially among pregnant individuals.

HPV vaccination was highly effective against anal HPV in a cohort of HIV-negative MSM, particularly when vaccination occurred at younger ages.

For adults aged 30 to 49 years, there has been a decline in melanoma incidence and mortality, according to study findings.